Market Research Logo

Hyperoxaluria - Pipeline Review, H2 2016

Hyperoxaluria - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperoxaluria – Pipeline Review, H2 2016, provides an overview of the Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape.

Hyperoxaluria is defined by the presence of excess amounts of oxalic acid (oxalate) in the urine. Symptoms include severe or sudden abdominal or flank pain, blood in the urine, fever and chills, loss of appetite, nausea and vomiting. Treatment includes a low-oxalate diet and vitamin B-6.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperoxaluria – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively.Hyperoxaluria.

Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperoxaluria (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Hyperoxaluria (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperoxaluria (Genito Urinary System And Sex Hormones)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperoxaluria (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Hyperoxaluria Overview
Therapeutics Development
Pipeline Products for Hyperoxaluria - Overview
Hyperoxaluria - Therapeutics under Development by Companies
Hyperoxaluria - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Hyperoxaluria - Products under Development by Companies
Hyperoxaluria - Companies Involved in Therapeutics Development
Allena Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
OxThera AB
Hyperoxaluria - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALLN-177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALLN-230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALN-GO1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCR-PHXC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oxabact - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperoxaluria - Dormant Projects
Hyperoxaluria - Discontinued Products
Hyperoxaluria - Product Development Milestones
Featured News & Press Releases
Oct 04, 2016: Allena Pharmaceuticals and Health Advances Present Analysis of Recurrent Kidney Stone Disease at the Academy of Managed Care Pharmacy Nexus Conference
Sep 07, 2016: Allena Pharmaceuticals Strengthens Leadership Team, Names Edward Wholihan as Chief Financial Officer and Robert Alexander, PhD, to Board of Directors
May 05, 2016: FDA Grants Orphan Drug Designation to Allena’s Investigational Therapy for the Treatment of Pediatric Hyperoxaluria
Feb 10, 2016: Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ALLN-177 for Secondary Hyperoxaluria
Nov 12, 2015: Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week
Nov 04, 2015: Allena Pharmaceuticals to Present Phase 2 Data on ALLN-177 Program at ASN Kidney Week 2015
Aug 04, 2015: Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria
Mar 18, 2015: Allena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the Treatment of Hyperoxaluria
Nov 17, 2014: Allena Pharmaceuticals Presents Phase 1 Data On ALLN-177 At American Society Of Nephrology Kidney Week 2014
Nov 10, 2014: Allena Pharmaceuticals To Present Data on Lead Program ALLN-177 at ASN Kidney Week 2014
May 15, 2014: OxThera Strengthens Patent Portfolio for Treatment of Hyperoxaluria
Apr 29, 2014: Allena Pharmaceuticals Announces Positive Phase 1 Data of ALLN-177 for the Treatment of Kidney Stones
Jan 08, 2014: OxThera Initiates Clinical Trial in Primary Hyperoxaluria
Jun 04, 2013: OxThera Strengthens Patent Portfolio For Orphan Disease
Jun 07, 2012: OxThera Resumes Clinical Development Of Oxabact For Treatment Of Hyperoxaluria
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hyperoxaluria, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Hyperoxaluria - Pipeline by Allena Pharmaceuticals Inc, H2 2016
Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016
Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016
Hyperoxaluria - Pipeline by OxThera AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hyperoxaluria - Dormant Projects, H2 2016
Hyperoxaluria - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Hyperoxaluria, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report